Table 1. Patient attributes.

		Mean ± Standard deviation
Age (year)		59.6 ± 12.2
		n	%
Stage
	1	15	31.9
	2	21	44.7
	3	5	10.6
	4	6	12.8
PS
	0	43	91.5
	1	1	2.1
	2	3	6.4
HER2
	(+)	38	80.9
	(-)	9	19.1
ER
	(+)	31	66.0
	(-)	8	17.0
	(±)	8	17.0
PgR
	(+)	8	17.0
	(-)	24	51.1
	(±)	15	31.9
Purpose of chemotherapy
	Adjuvant	25	53.2
	Neoadjuvant	17	36.2
	Symptom relief	5	10.6
Regimen
	EC (every 3w)	17	36.2
	TRZ+nabPTX (every 3w)	5	10.6
	TC (every 3w)	5	10.6
	3w-nabPTX (every 3w)	4	8.5
	LPR (every 4w)	3	6.4
	FUL (every 4w)	3	6.4
	CMF (every 3w)	3	6.4
	3w-TRZ+CMF (every 3w)	3	6.4
	TRZ (every 3w)	2	4.3
	3w-TRZ+DOC (every 3w)	2	4.3
Marital status
	Married	39	83.0
	Unmarried	8	17.0
Cohabitants
	Yes	46	97.9
	No	1	2.1
Current occupation
	Unemployed, housewife, student	28	59.6
	Temporary employment, part-time employment	10	21.3
	Company employee, self-employed	6	12.8
	Public official	0	0.0
	Other	3	6.4
Occupation before diagnosis
	Unemployed, housewife, student	19	40.4
	Temporary employment, part-time employment	17	36.2
	Company employee, self-employed	8	17.0
	Public official	0	0.0
	Other	3	6.4
Education
	Junior school graduate	12	25.5
	High school graduate	18	38.3
	Vocational school, junior college, technical school graduate	14	29.8
	University graduate, postgraduate	3	6.4
Experience as a healthcare professional
	Currently a healthcare professional	0	0.0
	Was a healthcare professional in the past	2	4.3
	Was not a healthcare professional in the past	45	95.7

PS: performance status, HER2: human epidermal growth factor receptor type 2, ER: estrogen receptor, PgR: progesterone receptor, EC: epirubicin/cyclophosphamide、TC: docetaxel/cyclophosphamide, TRZ: trastuzumab, DOC: docetaxel, LPR: leuprorelin, FUL: fulvestrant, CMF: cyclophosphamide/methotrexate/fluorouracil, nabPTX: nab-paclitaxel, 3w: 3 weeks, 4w: 4 weeks.